Anti-Calcitonin Gene-Related Peptide Monoclonal Antibodies in the Treatment of Patients With Concussion
Sign Up to like & getrecommendations! Published in 2022 at "Neurology"
DOI: 10.1212/01.wnl.0000801812.93958.f8
Abstract: Objective Investigate the efficacy of 3 anti-Calcitonin Gene-Related Peptide monoclonal antibodies (anti-CGRP mAbs), fremanezumab, galcanezumab, and erenumab, in concussion patients with post-traumatic headache (PTH) with a migraine phenotype. Background A study using monoclonal antibodies in… read more here.
Keywords: headache; cgrp mabs; treatment; anti cgrp ... See more keywords
Late Response to Anti-CGRP Monoclonal Antibodies in Migraine: A Multicenter, Prospective, Observational Study.
Sign Up to like & getrecommendations! Published in 2023 at "Neurology"
DOI: 10.1212/wnl.0000000000207292
Abstract: OBJECTIVES To assess frequency and characteristics of late responders (>12 weeks) to monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP). METHODS This is a multicenter (n=16), prospective, real-life study, considering all consecutive adults with… read more here.
Keywords: multicenter prospective; cgrp mabs; late responders; monoclonal antibodies ... See more keywords
Pooled Analysis of Real-World Evidence Supports Anti-CGRP mAbs and OnabotulinumtoxinA Combined Trial in Chronic Migraine
Sign Up to like & getrecommendations! Published in 2022 at "Toxins"
DOI: 10.3390/toxins14080529
Abstract: OnabotulinumtoxinA, targeting the CGRP machinery, has been approved for the last two decades for chronic migraine prevention. The recently approved monoclonal antibodies (mAbs) directed towards the calcitonin gene-related peptide (CGRP) pathway open a new age… read more here.
Keywords: mabs onabotulinumtoxina; cgrp mabs; chronic migraine; evidence ... See more keywords